1. The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma
- Author
-
Akiyoshi, Kinoshita, Noriko, Hagiwara, Akiyuki, Osawa, Takafumi, Akasu, Yoshihiro, Matsumoto, Kaoru, Ueda, Chisato, Saeki, Tsunekazu, Oikawa, Kazuhiko, Koike, and Masayuki, Saruta
- Subjects
Pharmacology ,Cancer Research ,Carcinoma, Hepatocellular ,Phenylurea Compounds ,Liver Neoplasms ,Nutritional Status ,Prognosis ,General Biochemistry, Genetics and Molecular Biology ,Nutrition Assessment ,Risk Factors ,Quinolines ,Humans ,Geriatric Assessment ,Aged ,Retrospective Studies ,Research Article - Abstract
Background/Aim: We aimed to investigate the association between The Geriatric Nutritional Risk Index (GNRI) and the tolerability of lenvatinib in patients with hepatocellular carcinoma (HCC). Patients and Methods: We retrospectively evaluated 61 HCC patients treated with lenvatinib and compared those with low GNRI (≤98, n=26) to those with high GNRI (>98, n=35). Results: The discontinuation of lenvatinib due to adverse events was more frequent in the low GNRI group (46.2%) than in the high GNRI group (17.1%) (p=0.014). Multivariate analysis revealed that low GNRI (p=0.014), hypothyroidism (model 1 p=0.021, model 2 p=0.013), and advanced age (p=0.026) were independently associated with the discontinuation of lenvatinib. The progression-free survival in the low GNRI group was significantly shorter than that in the high GNRI group (p=0.047). Conclusion: The GNRI might be independently associated with the tolerability of lenvatinib in patients with HCC.
- Published
- 2022
- Full Text
- View/download PDF